Skip to main content

Pediatric Growth Hormone Deficiency News

FDA Approves Once-Weekly Sogroya for the Treatment of Children Living with Growth Hormone Deficiency

PLAINSBORO, NJ, April 28, 2023 – Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 1...

FDA Approves Ngenla (somatrogon-ghla) Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

NEW YORK & MIAMI--(BUSINESS WIRE) June 28, 2023 – Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved Ngenla...

FDA Approves Skytrofa (lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Pediatric Growth Hormone Deficiency

COPENHAGEN, Denmark, Aug. 25, 2021 (GLOBE NEWSWIRE) – Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new...

Novo Nordisk Receives FDA Approval for Norditropin FlexPro for Growth Hormone Treatment

PRINCETON, N.J., March 3, 2010 /PRNewswire/ – Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved Norditropin FlexPro (somatropin [rDNA origin] injection), a...

Ask a question

To post your own question to our community, sign in or create an account.